Companies: 10,795·Total market cap: $144.5T
Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.

CLDXNASDAQHealthcare● Active
$28.52
$-0.10(-0.34%)
Market Cap$1.9B
P/E Ratio
52W High$35.79
52W Low$19.25
Overview

Celldex Therapeutics, Inc. (CLDX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · CLDX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-4.27cldx eps ttm · cldx earnings per shareEarnings history
PE Ratio (TTM)cldx pe ratio ttm · cldx price to earningsPE Ratio deep dive
Revenue (TTM)820000.00cldx revenue ttm · cldx annual revenueFull revenue history
Dividend YieldNo Dividenddoes cldx pay dividends · cldx dividend yieldDividend history
Shares Outstanding66.5Mcldx shares outstanding · cldx floatShares outstanding history
Next EarningsAug 6, 2026Est.cldx earnings date · cldx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$1.5M▼ 78.63% YoY
202320242025
celldex therapeutics, inc. revenue · cldx revenue 2025
FY 2025Net Income-$258.8M▼ 63.94% YoY
202320242025
celldex therapeutics, inc. net income · cldx profit 2025
FY 2025EPS$-3.90▼ 59.18% YoY
202320242025
cldx eps · celldex therapeutics, inc. earnings per share 2025
TTM:Revenue: $820000.00Net Income: -$283.7MEPS: $-4.27View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy19 analystsis cldx a buy · cldx analyst rating
Strong Buy
0
Buy
17
Hold
2
Sell
0
Strong Sell
0
12-Month Price Target
$48.00Low
$28.52Current
$51.00Avg Target78.80% upside
$54.00High
cldx price target · cldx 12 month forecast

Total: 19 · Buy rate: 89.5%

The CLDX analyst consensus is Buy, based on ratings from 19 Wall Street analysts over the past 3 months. The average 12-month price target is $51.00, representing +78.80% upside from the current price of $28.52.

Stock Performance

Full History
1D-4.38%
1W-0.97%
1M-15.75%
3M-2.75%
YTD+5.38%
1Y+38.19%
5Y-3.47%

About Celldex Therapeutics, Inc.

CEOAnthony S. Marucci
IPO DateMay 15, 1986
Employees186
CountryUS

Celldex Therapeutics, Inc. a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antib…

what is celldex therapeutics, inc. · cldx stock overview · celldex therapeutics, inc. company profile · who is celldex therapeutics, inc. ceo · cldx NASDAQ · celldex therapeutics, inc. headquarters · celldex therapeutics, inc. business segments

About Stock Overview & Key Data

Celldex Therapeutics, Inc. (CLDX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 15, 1986. As of the latest trading session, CLDX stock price is $28.52, with a market capitalization of $1.9B. The stock has returned +38.19% over the past 12 months and +5.38% year-to-date.

According to 19 Wall Street analysts, the consensus rating for Celldex Therapeutics, Inc. stock is Buy, with an average 12-month price target of $51.00. In fiscal year 2025, Celldex Therapeutics, Inc. reported revenue of $1.5M and net income of -$258.8M. For detailed data — including Celldex Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Celldex Therapeutics, Inc. (CLDX) stock price is $28.52. The stock is traded on NASDAQ under the ticker symbol CLDX. The 52-week range is $19.25 – $35.79.

CLDX stock priceCLDX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice